Terman et al
The litigation continues to evolve as additional plaintiffs file claims involving GLP-1 medications manufactured by Novo Nordisk and Eli Lilly, including Ozempic, Wegovy, Mounjaro, Zepbound, and related drugs
Clinical significance of erythroferrone and bone morphogenetic protein-6 in patients with anemia in the course of inflammatory bowel disease
One such option is semaglutide, which is marketed under several brand names including Ozempic (for type 2 diabetes), Wegovy (for obesity), and Rybelsus (an oral version used for type 2 diabetes)
Combining phentermine and Wegovy (semaglutide) is not recommended because both drugs affect appetite through different mechanismsphentermine stimulates your nervous system while semaglutide activates GLP-1 receptorscreating unpredictable cardiovascular effects and increasing the risk of heart palpitations, elevated blood pressure, and arrhythmias
The BRAT diet approach (bananas, rice, applesauce, toast) is often recommended, but it is terrible for protein intake
